About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Tennessee | 340 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 340 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 241-260 of 340 trials

RecruitingA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaThe purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with…NCT06581406·Scottsdale, Arizona and 32 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedSafety Study of MGA271 in Refractory CancerThe purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.NCT01391143·Los Angeles, California and 11 others

CompletedGlycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.NCT05259696·La Jolla, California and 12 others

CompletedA Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsThe purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D)…NCT05668585·Tucson, Arizona and 25 others

CompletedSafety Study of PLX4032 in Patients With Solid TumorsThe primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors.NCT00405587·Los Angeles, California and 6 others

Active not recruitingStudy of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsThis is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1)…NCT04521686·Phoenix, Arizona and 32 others

CompletedPhase I Dose Escalation Study for VIP152 in Patients With Advanced CancerDetermine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in…NCT02635672·Springdale, Arkansas and 15 others

CompletedNAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated…NCT05340621·Phoenix, Arizona and 11 others

CompletedPh1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC.NCT02437136·New Haven, Connecticut and 10 others

Active not recruitingStudy of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.This is a phase I/Ib, open label study.NCT03891953·Boston, Massachusetts and 8 others

CompletedPhase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to…NCT01844505·Gilbert, Arizona and 149 others

TerminatedA Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination…NCT02554812·Encinitas, California and 87 others

CompletedA Study of Tasisulam in Treating Participants With Malignant MelanomaThe primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic…NCT00383292·Los Angeles, California and 12 others

Active not recruitingA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsTScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell…NCT05973487·Scottsdale, Arizona and 20 others

CompletedStudy Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaTwo-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3…NCT01763164·Fayetteville, Arkansas and 228 others

CompletedStudy in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyThis study evaluates the different patterns of care for patients who have unresectable or metastatic melanoma.NCT02780089·Muscle Shoals, Alabama and 65 others

CompletedA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for…NCT00600496·Detroit, Michigan and 3 others

AvailableExpanded Access Program of AMTAGVI That is Out of Specification for Commercial ReleaseThe objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.NCT05398640·Gilbert, Arizona and 47 others

RecruitingA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsThis is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with…NCT05592626·Sacramento, California and 18 others

CompletedPretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A AntibodyHu14.18K322A is a monoclonal antibody developed at St. Jude Children's Research Hospital (SJCRH) that is made to bind to cancer cells that have a molecule called GD2 on their…NCT02159443·Memphis, Tennessee

PreviousPage 13 of 17Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma